预测肥胖风险的多组件 (生物) 标志物:一个范围审查协议
Farhad Vahid1, Coralie Dessenne2, Josep A Tur3
1Department of Precision Health, Luxembourg Institute of Health, Strassen, Luxembourg.
BMJ open
|March 8, 2024
概括
肥胖需要多组分生物标志物来进行有效的风险评估. 这一范围审查映射了当前关于结合各种标记物的研究,包括遗传学和生活方式,以获得更好的肥胖预防策略.
科学领域:
- 生物医学科学 生物医学科学
- 公共卫生 公共卫生
- 数据科学是数据科学.
背景情况:
- 全球肥胖率的上升需要先进的预防策略.
- 单个生物标志物对于准确的肥胖风险分层是不够的.
- 肥胖的多因素性质需要综合评估方法.
研究的目的:
- 对肥胖的多元组件 (生物) 标志物进行范围审查.
- 将各种肥胖风险生物标志物结合起来,绘制最先进的状态.
- 评估这些组合生物标志物的可用性和有效性.
主要方法:
- 使用多个数据库 (PubMed,Scopus,CINAHL,Embase) 的范围审查协议.
- 系统地搜索同行评审的文章,直到2024年1月.
- 根据PRISMA-ScR指南的独立审稿人进行两步的摘要和全文审查.
主要成果:
- 识别和绘制结合来自不同领域的至少两个生物标志物的研究.
- 分析古典标记物,多组学,生活方式,心理特征和肠道微生物群.
- 专注于整合和解释这些不同的数据类型,可能使用机器学习.
结论:
- 对当前关于肥胖多元组分生物标志物的研究有全面的了解.
- 关于预防肥胖的未来研究方向的指导.
- 开发更有效,个性化和多元组件肥胖干预措施的基础.
相关概念视频
01:24Obesity
498
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
498
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
126
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
126